AHAnsgar Heck

Ansgar Heck

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ansgar Heck has a total of 178 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tumor expression of dopamine receptor and prolactin is associated with acute dopamine agonist response in acromegaly

    by Shahriar Atai, Merisa Abusdal, Maren Ileby Wessel, Olivera Casar-Borota, Kristin Astrid Øystese, Jacob Winther, Jens Bollerslev, Ansgar Heck

    Objectives: In acromegaly, primary treatment is usually pituitary surgery. Remission rates are approximately 50% with pituitary tumor size and invasiveness playing important roles. Medical therapy is the secondary treatment for many patients. Yet, dopamine agonist responsiveness is variable, and reliable prognostic markers are lacking. We aimed to identify markers of dopamine agonist responsiveness. We hypothesized that (i) dopamine agonist response correlates with high dopamine receptor D2 expression and prolactin expression and secretion and (ii) estrogen receptor α expression is associated with tumor properties. Design: Single-center retrospective cohort analysis with treatment-naive patients who had undergone a bromocriptine test as a marker for dopamine agonist response. Methods: Sixty-nine patients with newly diagnosed acromegaly between 2008 and 2017 were included. During this period, the bromocriptine test was performed routinely at our center. Baseline hormone concentrations and MR images were evaluated retrospectively. Immunohistochemical staining of hormones and receptors and gene expression of dopamine receptor D2 in tumor tissue were performed and assessed. Results: Dopamine agonist test response and high dopamine receptor D2 gene expression were correlated ( r = 0.53; p ≤ 0.001), and both were associated with higher serum prolactin concentration and tumor prolactin expression, assessed by immunohistochemistry. Prolactin and estrogen receptor α expression were correlated, and strong expression was associated with smaller and less invasive tumors. Conclusions: Dopamine receptor D2 and prolactin expression are markers for dopamine agonist test response, providing valuable insights for personalized management and optimization of medical therapy in patients with acromegaly. Although prolactin and estrogen receptor α expression may be associated with tumor growth, the clinical applicability remains unclear.

  • Open Access

    Continuous white-light/indocyanine green overlay endoscopy in pituitary adenoma surgery: A prospective feasibility and safety study

    by Ida Olesrud, Martin K. Andersen, Christopher Larsson, Ansgar Heck, Daniel Dahlberg, Markus K.H. Wiedmann


  • Open Access

    Management of acromegaly beyond primary surgery: efficacy and safety of repeat surgery and radiotherapy

    by Shahriar Atai, Markus Wiedmann, Daniel Dahlberg, Jens Bollerslev, Ansgar Heck

    Introduction and purpose: Re-intervention, either transsphenoidal surgery or radiotherapy, is suggested in patients who are not in remission after primary surgery for acromegaly; however, the evidence is weak. We aimed to assess the remission rate after re-intervention, and complications compared to a comparison group who had undergone primary interventions only. Methods: Patients diagnosed with acromegaly between 2005–2021 at Oslo University Hospital were screened for inclusion. The study cohort included patients with two or more interventions. The comparison group included patients not in remission after primary surgery. Results: Of 223 patients with acromegaly, 42 underwent re-interventions (study cohort). At diagnosis, median age was 38 (IQR 29–48) years and 41 patients (98%) had a macroadenoma. The comparison group consisted of 49 patients, median age 54 (IQR 44–60) years and 37 (76%) had a macroadenoma at diagnosis. Re-interventions in the study cohort consisted of surgery, radiotherapy and a combination of these (22, 12 and eight patients). After re-interventions, 22 patients (52%) were in remission and 12 (29%) had reduced disease activity. Seven patients (17%) acquired new hormone deficiencies, two of them corticotroph deficiency. One patient in remission developed spinal fluid leakage and meningitis. There was no significant difference in complications after surgery between the study cohort and the comparison group. Conclusion: Re-interventions were safe and resulted in remission or substantial improvement in most patients. Re-intervention should be considered for patients who would otherwise require lifelong medical treatment.

  • Open Access

    rhPTH(1-84) for hypoparathyroidism: a randomized study of patient-reported outcomes

    by Maria Luisa Brandi, Tamara Vokes, Natasha M Appelman-Dijkstra, Olulade Ayodele, Brigitte Decallonne, Renate de Jongh, Manuel Díaz-Curiel, William Fraser, Richard D Finkelman, Ansgar Heck, et al.

    Objective: To assess the impact of recombinant human parathyroid hormone (1-84) [rhPTH(1-84)] compared with placebo, in combination with conventional therapy with vitamin D and/or calcium supplements, on health-related quality of life (HRQoL) in patients with symptomatic chronic hypoparathyroidism (cHypoPT). Design: Randomized, double-blind, placebo-controlled, phase 3b-4 study (ClinicalTrials.gov ID: NCT03324880). Methods: Eligible patients with symptomatic cHypoPT were randomized to receive subcutaneous rhPTH(1-84) 25-100 µg/day or placebo. The primary endpoint was the change from baseline to week 26 in Hypoparathyroidism Symptom Diary (HypoPT-SD) symptom subscale score. Key secondary endpoints were changes from baseline to week 26 in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue and in 36-item Short Form Health Survey physical component summary (SF-36v2 PCS). Results: In total, 93 patients were randomized to receive treatment: 45 received rhPTH(1-84) and 48 received placebo. Change from baseline to week 26 in HypoPT-SD symptom subscale score was significantly greater (improved) in the rhPTH(1-84) group than in the placebo group (difference in least-squares mean changes, −0.53; 95% confidence interval, −0.90 to −0.15, P = .003). Key secondary endpoints, changes between baseline and week 26 in the FACIT-Fatigue and SF-36v2 PCS scores were also significantly greater (improved) in the rhPTH(1-84) group than in the placebo group. The safety profile of rhPTH(1-84) was consistent with previous findings, and no new safety signals were identified. Conclusions: rhPTH(1-84) alongside conventional therapy improved symptom burden (as measured by the HypoPT-SD) and HRQoL to a greater extent than conventional therapy alone in patients with symptomatic cHypoPT.


  • Open Access

    Pasireotide as first line medical therapy for selected patients with acromegaly

    by Nicoleta C. Olarescu, Anders P. Jørgensen, Shahriar Atai, Markus K.H. Wiedmann, Daniel Dahlberg, Jens Bollerslev, Ansgar Heck

    Background and purpose: In acromegaly, growth hormone (GH) excess and pituitary tumours are typically managed through transsphenoidal surgery, often in combination with somatostatin receptor ligands (SRLs) given either before or following surgery. Although first-generation SRLs (lanreotide and octreotide) are efficacious in many patients, some exhibit resistance. Methods: We present the efficacy of the second-generation SRL, pasireotide, in six patients anticipated to be resistant to first-generation SRLs. The patients had large, hyperintense tumors on T2-weighted MRI and sparse granulation pattern by histology. Results: Over three to eight months, pasireotide reduced tumour volume in all patients and improved GH and IGF-1 levels. Visual field defects normalised. Despite hyperglycemia, requiring antidiabetic treatment in two patients, pasireotide proved effective as a first pharmacological therapy. Conclusion: This series supports the use of pasireotide for rapid tumour control and GH reduction, in selected patients with complex and large tumours, likely to be resistant to first-generation SRLs. This approach expands the therapeutic options for managing the most challenging cases enhancing the potential for other subsequent treatment modalities.


  • Open Access

    Indocyanine green fluorescence in endoscopic transsphenoidal resection of pituitary neuroendocrine tumors: a systematic review

    by Ida Olesrud, Ingeborg Janshaug Halvorsen, Marit Aarvaag Storaker, Ansgar Heck, Daniel Dahlberg, Markus K. H. Wiedmann

    Background: Over the last decade, endoscope integrated indocyanine green (E-ICG) fluorescence has been introduced in endoscopic skull base surgery. E-ICG seems to be a promising tool for intraoperative tissue differentiation, distinguishing pituitary neuroendocrine tumors (PitNET) from pituitary gland. More recent technical advancements have made E-ICG with simultaneous near-infrared/white-light overlay imaging available. E-ICG may improve intraoperative tumor identification, enabling more precise surgery and ultimately improved patient outcome. This systematic review evaluates the use of E-ICG for PitNET surgery. Methods: A systematic review was performed in accordance with PRISMA guidelines. PubMed, EMBASE, MedLine and Scopus databases were searched using different terms for “pituitary adenoma” combined with “Indocyanine green”. Data from relevant original papers were extracted and analyzed. Results: Fifteen studies were included in the final analysis. The studies employed different ICG administration and fluorescence assessment protocols. Endpoints and methodology were heterogenous. Study populations varied from one to 39 cases. A total of 193 patients underwent transsphenoidal endoscopic surgery with E-ICG for PitNET. ICG dosage varied from 5 mg to 25 mg/kg. Thirteen studies administered ICG intraoperatively. Eleven studies utilized first-generation endoscopes, requiring toggling between near infrared light fluorescence and white light. Second generation dual or overlay mode endoscopes were used in four studies. Tumor fluorescence was assessed in eleven studies (141 cases). Six studies utilized a quantitative method to assess ICG-fluorescence. Seven studies specifically reported surgical complications. No safety issues regarding ICG use were reported. Conclusions: The current literature is mainly based on small single center cohorts and case-studies, presenting a wide variety of approaches. Procedures and intraoperative assessment of fluorescence were mainly performed utilizing first-generation ICG endoscopes. There is lack of consensus in terms of ICG as an intraoperative tumor marker. Endoscopic ICG seems a promising tool for intraoperative real-time tissue differentiation, including vascular structures, tumor and pituitary gland.


  • Precision Medicine in Acromegaly: The Potential of Multimodal Therapy

    by Jens Bollerslev, Ansgar Heck

    Acromegaly is an orphan and debilitating disease calling for specialized management by highly experienced multidisciplinary teams. Surgery is the only curative therapy and is regarded as first-line management in most newly diagnosed cases ( 1). Although surgical techniques have improved over recent decades, the surgical cure rates remain modest and steady even in experienced centers ( 2). Thereby, clinical treatment algorithms have changed markedly often applying primary medical therapy as a first- or second-line option in relation to surgery, guided by the development of biomarkers for responsiveness ( 3). However, despite improved awareness of rare diseases, the diagnostic delay is still considerable for acromegaly and reported to be 6 to 10 years in various series, thereby linked to morbidity and mortality ( 4). Thus, there is a need for improvements in diagnosis by the development of even more sensitive biomarkers. With the recent changes in overall management and the introduction and availability of medical therapy even in combination, overall mortality has declined and even normalized in larger series published during the last 15 years, as reviewed ( 3), in accordance with the most recent studies ( 5). However, comorbidities in acromegaly are often coupled to various degenerative processes and seem to be disappointingly steady ( 6). This relative paradox might be explained by the fact that despite sensitive biomarkers for disease control, up to a third of patients participating in real-life studies still seem to be inadequately treated, as a result of strict and modern criteria for biochemical control ( 1, 3). Another point in relation to the longstanding morbidity in acromegaly is the risk of harm by excessive surgery, traditional radiotherapy, and potential medical overtreatment ( 3).

  • Open Access

    No effect of surgery on kidney and cardiovascular risk factors in mild primary hyperparathyroidism: secondary analyses from a 10-year randomized controlled trial

    by Ansgar Heck, Mikkel Pretorius, Karolina Lundstam, Kristin Godang, Mikael Hellström, Thor Ueland, Jens Bollerslev

    Objective: Renal function and the skeleton are classic target organs in primary hyperparathyroidism (PHPT), affected by the chronic course of the disease. Most patients diagnosed today exhibit mild PHPT, characterized by slight hypercalcemia and no or unspecific symptoms. Concerns have been raised that PHPT could promote deteriorating kidney function and increase cardiovascular risk directly. To examine the effect of parathyroidectomy (PTX) on mild PHPT on renal function and markers for bone turnover, cardiovascular disease (CVD), and vascular inflammation. Design: Prospective randomized controlled trial. ClinicalTrials.gov: NCT00522028. Setting: Eight Scandinavian referral centers. Participants: From 1998 to 2005, 191 patients with mild PHPT were included in Sweden, Norway, and Denmark. Of these 150 were included in the present analyses. Intervention: Seventy patients were randomized to PTX and 80 to observation without intervention (OBS). Measures: e-GFR was calculated based on creatinine and cystatin C. Markers of CVD and systemic inflammation: osteoprotegerin, vascular cell adhesion molecule 1, soluble CD40 ligand, interleukin-1 receptor antagonist, von Willebrand factor. Bone turnover markers: C-terminal telopeptide of type 1 collagen (CTX-1) and serum Procollagen type 1 N-terminal propeptide. Results: No differences in the development of renal function or vascular and systemic inflammation were detected. CTX-1 was lower in PTX after 10 years. Limitations: Secondary analyses of a randomized controlled trial. Conclusion: PTX does not appear to affect renal function or markers of CVD and vascular inflammation in mild PHPT in a ten-year perspective.


  • Unravelling pituitary tumours in medically treated patients with acromegaly: the impact of systematic MRI reassessment

    by Shahriar Atai, Martin Knudtzon Andersen, Markus Wiedmann, Daniel Dahlberg, Kristin Astrid B Øystese, Jens Bollerslev, Geir Ringstad, Ansgar Heck

    Background: In acromegaly, the primary tumor is usually found during magnetic resonance imaging (MRI) of the pituitary gland. A remnant tumor after surgery is, however, harder to depict. When a tumor is missed, the remaining option is usually lifelong pharmacological treatment. Purpose: To identify tumors by reassessment of all available MRI scans in pharmacologically treated patients, operated or not, and to compare our results with the routine MRI reports. Material and Methods: Adult patients diagnosed with acromegaly and managed at a tertiary care center between 2005 and 2021 and currently on pharmacological treatment were included. MRI scans were evaluated in a standardized manner and classified independently by a radiologist and an endocrinologist into “certain,” “suspected,” or “no tumor.” In case of disagreement, consensus was achieved with a senior neuroradiologist. The results were compared using the clinical radiologists’ routine MRI reports. Results: We identified certain and suspected tumors in 29/74 and 36/74 patients, respectively. No tumor was identified in nine patients. In five of these, no MRI contrast agent was given. Discrepancy between our results and the routine MRI reports was found in 31/74 patients ( P = 0.01). In 22 patients, the routine reports described no tumor while we identified certain tumors in 2/22 patients and suspected tumors in 13/22 patients. Conclusion: In most patients with pharmacologically treated acromegaly, we identified a certain or suspected pituitary tumor. These findings were more frequent compared to the routine MRI reports. Based on our results, patients will be considered for a change in long-term treatment modality.


  • Open Access

    Long-term depot specific changes in adipose tissue after treatment of acromegaly

    by Camilla M Falch, Kristin Godang, Tove Lekva, Thor Ueland, Ansgar Heck, Jens Bollerslev, Nicoleta C Olarescu

    Context: Patients with active acromegaly present a decreased adipose tissue (AT) mass, and short-term studies show that treatment leads to AT depot-specific gain. However, it remains unclear if the increase is persistent in the long-term perspective and/or is sex-dependent. Design: To characterize the depot-specific changes of AT after treatment of acromegaly and identify contributing factors. Methods: Adipose tissue, including visceral (VAT), subcutaneous (SAT), and total (TAT), and android to gynoid ratio (A/G ratio) were measured by dual energy X-ray absorptiometry at diagnosis (n = 62), and after treatment at short-term (median (IQR) 1.9 (1.5-2.3)) and long-term 5.5 (3.9-9.5) years, and correlated to clinical and biochemical measurements. Growth hormone (GH), insulin-like growth factor 1 (IGF-1), glucose and HbA1c levels, gonadal status, and the presence of diabetes mellitus were recorded. Remission status was assessed at the long-term visit (IGF-1/ULN ≤ 1.3). Differences in the temporal course of AT from baseline to short- and long-term follow-up according to sex, diabetes, gonadal, and remission status were evaluated by mixed model analysis, adjusted for age. Results: Despite a stable body mass index, VAT and A/G ratio increased at both time points, whereas SAT mainly increased at short-term, plateauing afterwards (P < .05 for all). Visceral adipose tissue and A/G ratio were higher in men (P = .035 and P < .001), and the A/G ratio increased more than in women (P = .003). Glucose and HbA1c decreased short-term (P < .05) and remained stable at long-term. The increase in AT depots correlated with the decrease of disease activity at long-term. Remission status had no effect on changes in AT mass during follow-up. Conclusion: Treatment of acromegaly leads to an increase in AT mass in a depot- and sex-specific manner both at short-term and long-term follow-up. Glucose metabolism improves rapidly after disease control and persists.